Longboard Pharmaceuticals, Inc.
LBPHDelisted Dec 2, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001832168
Longboard Pharmaceuticals, Inc. was delisted on Dec 2, 2024; its insiders filed their last Form 4 on Dec 2, 2024; 125 institutions reported holding it in 13F filings for Q3 2024, worth $1.33B in total; Viking Global Investors was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 125
- Q3 2024, +26 vs. previous quarter
- 13F value
- $1.33B
- Reported value at the end of Q3 2024
- Superinvestors holding
- 1
- At the end of Q3 2024
Superinvestors holding LBPH, Q3 2024
1 superinvestor reports holding Longboard Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.2%
Longboard Pharmaceuticals, Inc.'s share of the portfolio
- Shares
- 1,969,041
- Value
- $65.6M
Latest insider trades
Open-market purchases and sales by Longboard Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 2024 (view filing) | Oct 15 | 1 day | Kaye RandallCMO | SSale | −16.7K | $59.04 | −$984.0K | −48.2%17.9K after | 10b5-1 |
| Sep 16, 2024 (view filing) | Sep 16 | Same day | Kaye RandallCMO | SSale | −16.7K | $31.64 | −$527.3K | −48.2%17.9K after | 4 lots10b5-1 |
| Aug 13, 2024 (view filing) | Jan 23 | 203 daysLate | Kaye RandallCMO | PPurchase | +100 | $24.82 | +$2.48K | New position100 after | 10b5-1 |
| Aug 13, 2024 (view filing) | Jun 25 | 49 daysLate | Kaye RandallCMO | SSale | −100 | $20.87 | −$2.09K | −100.0%0 after | 10b5-1 |
| Aug 13, 2024 (view filing) | Aug 12 | 1 day | Kaye RandallCMO | SSale | −16.7K | $34.73 | −$578.8K | −48.2%17.9K after | 2 lots10b5-1 |
| Jan 29, 2024 (view filing) | Jan 25 | 4 days | Arena Pharmaceuticals IncOther: Former 10% Owner | SSaleVoting Common Stock | −3.98M | $24.25 | −$96.5M | −100.0%0 after |
Top 10 13F holders, Q3 2024
The largest institutional positions in Longboard Pharmaceuticals, Inc. at the end of Q3 2024; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 4,350,099 | $145.0M | 0.01% | −65,119−1.5% | Reduced |
| Farallon Capital Management, L.L.C. | 3,150,857 | $105.0M | 0.58% | +210,357+7.2% | Added |
| Price T Rowe Associates Inc | 2,909,257 | $97.0M | 0.01% | +400,721+16.0% | Added |
| BlackRock, Inc. | 2,837,880 | $94.6M | 0.00% | +2,837,880 | New |
| Cormorant Asset Management, LP | 2,790,462 | $93.0M | 4.93% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,033,068 | $67.8M | 0.00% | +107,921+5.6% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 1,969,041 | $65.6M | 0.24% | +310,079+18.7% | Added |
| Wellington Management Group LLP | 1,590,072 | $53.0M | 0.01% | −188,899−10.6% | Reduced |
| Polar Capital Holdings Plc | 1,102,740 | $36.8M | 0.22% | −251,765−18.6% | Reduced |
| Integral Health Asset Management, LLC | 1,050,000 | $35.0M | 4.12% | −50,000−4.5% | Reduced |